Endocrine Abstracts

Introduction: Diabetes mellitus (DM) is a common co-morbidity in patients with heart failure and reduced left ventricular ejection fraction (HF-REF), and is associated with adverse prognosis. Subgroup analyses of randomized controlled trials suggest patients with DM benefit prognostically from beta-adrenoreceptor blockers (BB) and angiotensin converting enzyme inhibitors (ACEi). However, it remains unclear whether escalating doses of these age...

Introduction: Diabetes mellitus (DM) is a common co-morbidity in patients with heart failure and reduced left ventricular ejection fraction (HF-REF), and is associated with adverse prognosis. Subgroup analyses of randomized controlled trials suggest patients with DM benefit prognostically from beta-adrenoreceptor blockers (BB) and angiotensin converting enzyme inhibitors (ACEi). However, it remains unclear whether escalating doses of these age...